echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Heyuan Bio 2021 3rd Scientific Advisory Committee Cell Therapy Symposium was successfully held, all

    Heyuan Bio 2021 3rd Scientific Advisory Committee Cell Therapy Symposium was successfully held, all

    • Last Update: 2021-02-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 17, 2021, Heyuan Biotech (Tianjin) Co., Ltd. (hereinafter referred to as Heyuan Bio) held the 3rd Scientific Advisory Committee Cell Therapy Seminar in 2021, which was successfully held by Professor Wang Jianxiang, Director of the National Center for Clinical Medicine of Blood System Diseases, Vice President of the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) and Chief Medical Health Officer of Guo investment. Scientists, former FDA senior clinical review experts, former CDE chief scientist Dr. He Rui chaired, Heyuan bioscience consultant experts and field experts and heyuan biological team on the company's core product CNCT19 cell injection clinical research planning and NDA declaration preparation, covering blood tumors and solid tumors multiple adaptive innovation pipeline layout and technology innovation platform construction and other content of in-depth discussions.
    The experts who attended the meeting were Professor Cheng Tao (in alphabetical order by surname Pinyin) Professor Han Weidong, Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) Professor Lan Gemstone of the PLA General Hospital Professor Liu Delong, Chairman of the Central Biotechnology and Pharmacy Working Committee of the Chinese Agricultural and Industrial Democratic Party Professor Qiu Zugui of the New York School of Medicine, Professor Song Yongping of the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology of the Chinese Academy of Medical Sciences) Dr. Wang Gang, Pharmaceutical Research Center Co., Ltd. Former senior ADVISER to the FDA and former CDE Chief Scientist Professor Wang Min, Professor Wang Weiyi, Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) Professor Yao Shuyuan, Institute of Zoology, Chinese Academy of Sciences, Professor Zhang Jianmin, Institute of Basic Medicine, Chinese Academy of Medical Sciences, Professor Zhou Renfu, First Affiliated Hospital of Zhengzhou University, Professor Of Hematology, Chinese Academy of Medical Sciences This seminar is the first annual meeting of Heyuan Bio following the important milestone of CNCT19 cell injection being included in the "Breakthrough Therapeutic Drugs" by the National Drug Administration in December 2020, and is also the third meeting of experts of scientific consultants of Heyuan Bio.
    Heyuan Bio CEO Dr. Lu Wei first introduced to the experts the company's achievements in the past year, in overcoming the impact of the epidemic, the core product CNCT19 cell injection first entered the registered clinical Phase II stage and obtained "breakthrough therapeutic drug identification", the comprehensive layout of gene editing and iPSCs innovation technology platform driven by international competitive pipeline products, and constantly improve the talent team and industrialization core capabilities, in the participation of experts to accelerate the strategic development of the core product and pipeline.
    The main topics of this seminar are accelerating the core product launch process, the orderly development of research and development pipeline and medium- and long-term research and development direction, including cnCT19 cell injection clinical research and registration declaration of steady progress and action plan, as well as blood tumor dual target CAR-T pipeline products IND strategy research, gene editing and iPSCs and other innovative technology platforms in immunocellular therapy application prospects and direction, solid tumor adaptation expansion and breakthrough and other cutting-edge discussion.
    Professor Wang Jianxiang and Professor Yu Dehui of the Hematology Hospital of the Chinese Academy of Medical Sciences (Hematology Research of the Chinese Academy of Medical Sciences) introduced the clinical research data of the core product CNCT19 cell injection in detail, and the heyuan team introduced the planning of CNCT19 clinical research and NDA declaration preparation.
    In the pipeline products that are about to enter the IND stage, Professor Wang Min of the Hematology Hospital of the Chinese Academy of Medical Sciences (Hematology Research of the Chinese Academy of Medical Sciences) introduced the in vivo and in vivo studies of a variety of dual-target CAR-T products for blood tumors.
    During the discussion on medium- and long-term platform construction, Professor Cheng Tao of the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology of the Chinese Academy of Medical Sciences) presented the application prospects of immunocellular therapy platform based on human pluripotent stem cells (hPSC) and the latest research results of hpSC-CAR-T, hPSC-CAR-NK and hPSC-CAR-M.
    Professor Wang Weiyi of the Institute of Zoology of the Chinese Academy of Sciences explained the research on improved cell therapy on the gene editing technology platform, demonstrated that the immunosuppressive target gene editing CAR-T cells have significantly improved the ability of proliferation and tumor killing in the body, and are expected to achieve a breakthrough in the treatment of solid tumors, and suggested that the heyuan organisms speed up the preparation of relevant clinical research.
    Professor Zhang Yi of the First Affiliated Hospital of Zhengzhou University demonstrated the innovative design of CAR-T to change the micro-environment of solid tumors and enhance the anti-tumor effect of CAR-T in the treatment of solid tumors.
    The experts unanimously affirmed the breakthrough achievements made by Heyuan Bio in the past year, and unanimously recommended that Heyuan Bio-High Quality and High Efficiency promote the clinical research process for the registration of the core product CNCT19 cell injections, while making commercial preparations to bring the product to market as quickly as possible to benefit patients at competitive prices.
    in the pipeline layout, with CAR-T platform, iPSCs platform and gene editing platform and other technological innovation platform driven, deep into the field of blood tumor disease, breakthrough solid tumor, layout of universal immunocellular therapy technology platform.
    at the same time, the integration of multi-resources, to achieve breakthroughs, based on China, embrace the world.
    This meeting lasted a day and was fruitful and constructive, taking into account Heyuan Bio's achievement review since its inception and key plans for future growth, reflecting heyuan Bio's commitment and confidence in the company's development science, rigour and growth.
    experts have made great efforts to lay a solid foundation for the development of heyuan organisms in 2021 and pointed out the direction of development. Professor Wang Jianxiang and Professor He Rui, Chairman of the
    Conference, concluded that the heyuan biological team has excellent capabilities, excellent clinical research data for the pre-injection of the core product CNCT19 cells, and urgent clinical needs, with the support of the "breakthrough therapeutic drugs" policy and the strengthening of the guidance of regulatory agencies, to accelerate the process of clinical application.
    As one of the most promising immunocellular therapy innovative pharmaceutical companies in China, heyuan bio-power layout forward-looking, cutting-edge technological innovation platform, clinical demand-oriented, focus on advanced technology and quality control system construction, orderly development of differentiated and internationally competitive immunocellular therapy products, so that innovative cell drugs for the benefit of patients.
    Heyuan Biological CEO Dr. Lu Wei concluded: "It is a great honor to invite experts to participate in this meeting, to contribute to the next development of Heyuan Bio and provide strong and firm support, Heyuan Bio will continue to improve the core capacity-building of industrialization, accelerate the CNCT19 cell injection commercialization process; Comprehensively improve research and development capabilities, complete the CAR-T platform, iPSCs platform, gene editing platform multi-platform driving coverage of blood tumors, solid tumors and general heterogeneity applications of highly scalable pipeline layout; In-depth cooperation with first-class institutions, and effectively promote the deep integration of production, research and development of technological innovation mechanisms, so that innovative immunocell therapy more and faster access to clinical applications, to serve patients.
    About Heyuan Biotech (Tianjin) Co., Ltd. Heyuan Biotech (Tianjin) Co., Ltd. was founded in June 2018, is focused on immune cell therapy and other innovative drug research and development and commercialization of biomedical enterprises, in-depth cooperation with the national first-class hospitals and clinical research centers, is committed to building the industry-leading cell therapy drug research and development, clinical transformation and commercial platform to accelerate cell therapy technology innovation, clinical application and commercialization.
    's first core product CNCT19 cell injection is an independent intellectual property rights target CD19 CAR-T cell therapy products, derived from the Chinese Academy of Medical Sciences Hematology Hospital (Chinese Academy of Medical Sciences Institute of Hematology) long-term technological innovation accumulation.
    November 29, 2019, CNCT19 cell injections were approved by the National Drug Administration for two new drug clinical trials, clinical trials for the treatment of recurring or resusciable acute lymphoblastic leukemia (acceptance number: CXSL1800106) and clinical trials for the treatment of recurring or resusciable invasive B-cell non-Hodgkin lymphoma (acceptance number: CXSL1800107).
    Currently, both clinical trials have taken the lead in entering the registered Clinical Phase II phase and have been identified by the Drug Review Center of the State Drug Administration as a "breakthrough therapeutic drug" for relapsed or refractic acute lymphoblastic leukemia, which is expected to become the first independent intellectual property-targeted CD19 CAR-T product to be launched.
    adheres to meet clinical needs-oriented, through strict cell therapy product production and quality management system, for patients to create a safe, efficient and accessable immunocellular therapy products, and continue to create a highly scalable and internationally competitive innovative pipeline covering blood tumor pipelines, solid tumor pipelines and forward-looking universal platform pipelines.
    , the company has a world-class research and development technology platform, process development platform, quality control system and commercial production base.
    company has a 2,000m2 research and development center in Beijing and a nearly 10,000m2 GMP-compliant immunocell drug research and development and commercial production base in Tianjin.
    company has a number of invention patents, selected by the Ministry of Science and Technology national key research and development program projects, namely, "science and technology to help the economy 2020 key special projects."
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.